Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
01 juin 2024 08h00 HE
|
Purple Biotech Ltd.
26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs....
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
31 mai 2024 12h00 HE
|
Alberta Cancer Foundation
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
Local startup Oncobiotix
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
31 mai 2024 08h00 HE
|
Novartis Pharma AG
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs....
Johnson & Johnson MedTech gathers multi-disciplinary expert group to optimise lung cancer care and dialogue between patients and their healthcare team
30 mai 2024 08h39 HE
|
Johnson & Johnson MedTech
A recent European survey revealed that 80 percent of thoracic surgeons declared to follow the Enhanced Recovery After Surgery (ERAS) protocol, focussed on improving peri-operative lung cancer care,1...
Researchers Use Olink® Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis
30 mai 2024 08h00 HE
|
Olink Proteomics AB
Landmark study using the Olink Explore platform identifes proteins in the blood that may provide a 7-year warning for various cancers.
ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
30 mai 2024 08h00 HE
|
ImCheck Therapeutics SAS
ImCheck to Present Promising ICT01 Datafrom the EVICTION Study at ASCO 2024 Interim data from Phase I/II EVICTION study shows favorable safety profile and promising efficacy for ICT01 in combination...
'Les Voiles de l'Espoir' arrives in Monaco on the 19th of June
29 mai 2024 04h54 HE
|
Yacht Club de Monaco
TURIN, Italy, May 29, 2024 (GLOBE NEWSWIRE) -- Supporting children aged 8 to 14 from all backgrounds (France, Morocco, Israel, Luxembourg, Belgium, Switzerland, and other countries) in remission...
Burning Rock Reports First Quarter 2024 Financial Results
29 mai 2024 01h34 HE
|
Burning Rock Biotech Limited
Burning Rock Reports First Quarter 2024 Financial Results
CARGO Therapeutics to Participate in Upcoming Investor Conferences
28 mai 2024 08h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
28 mai 2024 08h00 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing